Piper Sandler on Nektar Therapeutics (NKTR): 'A Perfect Opportunity to Own NKTR Ahead of Additional AD Data'
Tweet Send to a Friend
(Updated - September 15, 2025 8:32 AM EDT)
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $105.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $105.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
